2024
Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism
Eguren-Santamaría I, Rodríguez I, Herrero-Martin C, de Piérola E, Azpilikueta A, Sánchez-Gregorio S, Bolaños E, Gomis G, Molero-Glez P, Chacón E, Mínguez J, Chiva S, Diez-Caballero F, de Andrea C, Teijeira Á, Sanmamed M, Melero I. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism. OncoImmunology 2024, 13: 2373519. PMID: 38988823, PMCID: PMC11236292, DOI: 10.1080/2162402x.2024.2373519.Peer-Reviewed Original ResearchConceptsTumor fragmentsImmunotherapy combinationsIFNg productionActivation markersClinical response to PD-1 blockadeResponse to PD-1 blockadeAgonistic anti-CD137 mAbAnti-PD-1 treatmentAnti-CD137 mAbAnti-PD-1PD-1 blockadeSyngeneic immunocompetent miceInfiltrating T cellsShort-term cultureUnmet medical needAnti-CD137Contralateral tumorsBilateral tumorsCancer immunotherapyTissue culture supernatantsImmunocompetent miceSolid malignanciesT cellsMAb combinationsMouse tumors
2023
Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence
Chen J, Madina B, Ahmadi E, Yarovinsky T, Krady M, Meehan E, Wang I, Ye X, Pitmon E, Ma X, Almassian B, Nakaar V, Wang K. Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence. Acta Pharmaceutica Sinica B 2023, 14: 335-349. PMID: 38261838, PMCID: PMC10792965, DOI: 10.1016/j.apsb.2023.08.034.Peer-Reviewed Original ResearchCancer immunotherapyTumor recurrenceShort hairpin RNASurvival benefitIL-12Immune mechanismsLong-term survival benefitIL-17 receptor ACancer-promoting inflammationLarge established tumorsMultiple immune mechanismsPD-L1 pathwayT cell exhaustionDeath ligand 1Human cancer immunotherapySelf-amplifying mRNATumor-bearing miceVirus-like vesiclesMechanism of protectionCombined immunomodulationContralateral tumorsIL-17Established tumorsAbscopal effectImmunological memory
2016
Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming
Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, Labiano S, Sanmamed MF, Azpilikueta A, Bolaños E, Sanchez-Paulete AR, Aznar MA, Rouzaut A, Schalper KA, Jure-Kunkel M, Melero I. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. Cancer Research 2016, 76: 5994-6005. PMID: 27550452, DOI: 10.1158/0008-5472.can-16-0549.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalBasic-Leucine Zipper Transcription FactorsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansLymphocytes, Tumor-InfiltratingMiceMice, Inbred BALB CMice, Inbred C57BLNeoplasms, ExperimentalProgrammed Cell Death 1 ReceptorReceptor, Interferon alpha-betaRepressor ProteinsTumor MicroenvironmentTumor Necrosis Factor Receptor Superfamily, Member 9ConceptsAnti-CD137 mAbsCD8 T cellsEffector T cellsT cellsTumor lesionsMyeloid-derived suppressor cellsSelective depletion experimentsType I IFN systemTumor-infiltrating lymphocytesCombination of radiotherapyField of irradiationImmunostimulatory mAbsImmunotherapy combinationsIntracellular IFNγProimmune effectsContralateral tumorsSuppressor cellsDendritic cellsClinical evidenceRadiotherapy strategiesIrradiation regimenAntitumor effectsClinical developmentTumor siteEx vivo
1981
Risk of subsequent contralateral breast carcinoma in a population of patients with in‐situ breast carcinoma
Webber B, Heise H, Neifeld J, Costa J. Risk of subsequent contralateral breast carcinoma in a population of patients with in‐situ breast carcinoma. Cancer 1981, 47: 2928-2932. PMID: 6266644, DOI: 10.1002/1097-0142(19810615)47:12<2928::aid-cncr2820471232>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsBreast carcinomaContralateral carcinomaSubsequent cancerContralateral breast carcinomaMajority of patientsPopulation of patientsSecond breast cancerNoninvasive breast carcinomaSitu breast carcinomaContralateral tumorsOverall survivalContralateral breastHistological typeSurvival figuresLobular carcinomaOpposite breastBreast cancerSitu carcinomaCarcinomaS. womenCancerPatientsBreastWomenMastectomy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply